Skip to main content
14 search results for:

Ross Camidge 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 07-04-2022 | Channel

    ALK fusion-positive NSCLC: International approaches to management

    Ross Camidge leads Rosario García Campelo and Yongchang Zhang in a panel discussion on the detection and treatment of ALK fusion-positive NSCLC in current practice. 

  2. 16-11-2022 | Non-small-cell lung cancer | News | Article

    Telisotuzumab vedotin plus erlotinib may offer novel advanced NSCLC approach

    “Teliso-V plus erlotinib showed encouraging antitumor activity and acceptable toxicity” in patients who had previously been treated with an EGFR–tyrosine kinase inhibitor (TKI), report Ross Camidge (University of Colorado Cancer Center, Aurora, USA) and co-workers.

  3. play
    28-03-2022 | Non-small-cell lung cancer | Video

    ALK fusion-positive NSCLC: International approaches to management

    Ross Camidge leads Rosario García Campelo and Yongchang Zhang in a discussion on the detection and treatment of ALK fusion-positive NSCLC in current practice.

  4. 02-10-2019 | Non-small-cell lung cancer | Video | Article

    Expert highlights: Lung and thoracic cancers at ESMO 2019

    Ross Camidge comments on the advanced non-small-cell lung cancer research that caught his attention at the ESMO Congress 2019, including the FLAURA and CheckMate 227 overall survival data, and updates on brigatinib and lorlatinib (3:01).

  5. 08-09-2019 | Lung cancer | Video | Article

    Expert highlights from WCLC 2019

    WATCH  |   Advisory Board member Ross Camidge shares his top picks of the presentations at the 2019 World Conference on Lung Cancer, including the CASPIAN trial and the updated AMG 510 data (1:51).

  6. 15-06-2020 | FDA | News | Article
    approvalsWatch

    Brigatinib indication expanded in USA

    Speaking to medwireNews , lead author of the ALTA 1L trial D Ross Camidge (University of Colorado Cancer Center, Aurora, USA) said that “brigatinib now joins alectinib as a highly efficacious next generation ALK–TKI superior to crizotinib in the first line setting.”

  7. 01-06-2019 | Lung cancer | Video | Article

    Expert highlights: Lung cancer at ASCO 2019

    Advisory Board member Ross Camidge comments on his picks for the most exciting lung cancer research being presented at the 2019 ASCO Annual Meeting, including the RELAY trial and the ARROW trial of the RET inhibitor BLU-667 (3:13).

  8. play
    08-06-2018 | Lung cancer | ASCO 2018 | Video

    Expert highlights: An update from ASCO 2018 on targeted therapies in lung cancer

    Advisory Board member Ross Camidge takes us through the latest research on ALK inhibitors and other targeted therapies for lung cancer, including updated data from the ALEX trial (8:46).

  9. AMG 510 in NSCLC

    Presenting author Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the trial and the next steps for the research (5:34): Govidan video Advisory Board member Ross Camidge discusses the implications of this trial in his round-up of key data presented at WCLC 2019: Camidge video

  10. 11-06-2019 | Non-small-cell lung cancer | News | Article

    RELAY: Ramucirumab–erlotinib a potential first-line option for EGFR-mutated NSCLC

    And in a comment to medwireNews , Medicine Matters oncology Advisory Board member Ross Camidge (University of Colorado Cancer Center, Aurora, USA) questioned the relevance of the trial results given that erlotinib is no longer the preferential agent for first-line treatment in these patients, having been superseded by osimertinib.

  11. 21-09-2018 | Non-small-cell lung cancer | News | Article

    Brigatinib has intracranial activity in patients with ALK-rearranged NSCLC

    In light of these results and the previously reported findings for the overall populations of the trials, lead author D Ross Camidge (University of Colorado Cancer Center, Aurora, USA) and team speculate that “[b]rigatinib has broad preclinical activity against ALK mutations, which likely contributes to prolonged PFS systemically and potentially in the brain.”

  12. 03-10-2018 | Non-small-cell lung cancer | News | Article

    Brigatinib outplays crizotinib in ALK inhibitor-naïve advanced NSCLC

    Speaking to medwireNews , lead author D Ross Camidge (University of Colorado Cancer Center, Aurora, USA) commented that “despite only 9–11 months of follow-up across the two arms, brigatinib has already convincingly beaten crizotinib.”

  13. 13-06-2018 | Non-small-cell lung cancer | ASCO 2018 | Article
    News in brief

    Advanced NSCLC PFS gain with alectinib maintained with longer follow-up

    The PFS boost with alectinib was evident both in patients with and those without brain metastases at baseline (HR=0.35 and 0.47, respectively), as per a poster presented by Ross Camidge (University of Colorado Cancer Center, Aurora, USA) at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA.

  14. 05-12-2017 | Non-small-cell lung cancer | News | Article

    Adjuvant gefitinib could benefit patients with resected stage II–IIIA NSCLC

    In an accompanying comment , Terry Ng and D Ross Camidge, both from the University of Colorado Cancer Center in Aurora, USA, note: “The findings of ADJUVANT suggest many new avenues for clinical research, centred around an increased understanding that the disease-free survival advantage for adjuvant EGFR tyrosine kinase inhibitors could reflect effective suppression of tumour growth during treatment but ineffective cure of microscopic disease.”

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.